AMA submission to the Therapeutic Goods Administration – Proposed amendments to the Poisons Standard – June 2021
In this submission, the AMA responds to proposals to be considered by the Advisory Committee on Medicines Scheduling meeting for June 2021. The AMA continues to oppose the proposal to unscheduled amygdalin and hydrocyanic acid. The AMA supports the proposal to make all bufexamac products Schedule 4 (prescription only). The AMA opposes the proposal to include higher dose ibuprofen in Schedule 2 (600mg modified release tablets).